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Summary
Background: The ERK family of MAP kinase plays a crit-
ical role in growth factor-stimulated cell-cycle progres-
sion from G0/G1 to S phase. It has been suggested that
sustained activation, but not transient activation, of
ERK is necessary for inducing S phase entry. Although
the essential role of ERK MAP kinase in growth factor-
stimulated gene expression, especially expression of im-
mediate-early genes, is well established, it has remained
unclear how ERK activity duration affects the promotion
of G1 phase progression to S phase.
Results: We have found that inhibition of ERK activation
by the MEK inhibitor or dominant-negative MEK1 even
immediately before the onset of S phase leads to the
cessation of S phase entry. Our analyses reveal that
there are ERK-dependent downregulated genes, whose
expression levels return to their original levels rapidly
after ERK inactivation, and that their downregulation
mostly requires AP-1 activity. Remarkably, microinjec-
tion experiments demonstrate that many of the downre-
gulated genes act as antiproliferative genes during G1
phase and that their forced expression to the levels be-
fore growth factor stimulation even in late G1 phase
blocks S phase entry.
Conclusions: Thus, continuous ERK activation downre-
gulates antiproliferative genes until the onset of S phase
to allow successful G1 phase progression. This mecha-
nism may also work as a fail-safe mechanism, which
prevents inappropriate stimuli that induce transient
ERK activation from causing S phase entry.
Introduction
Mammalian cultured cells proliferate in the presence of
serum containing growth factors. When cultured fibro-
blasts are deprived of serum, they enter the quiescent
state, termed G0 phase. The addition of growth factors
induces the re-entry of the cell cycle: the quiescent cells
leave the G0 phase, progress through G1 phase, repli-
cate their DNA, and divide. Extracellular signal-regu-
lated kinase (ERK), a member of the MAPK family, is
*Correspondence: l50174@sakura.kudpc.kyoto-u.ac.jp
3 These authors contributed equally to this work.one of key molecules in growth factor signaling [1–9].
ERK is phosphorylated and activated by MEK in re-
sponse to growth factor stimulation, and activated
ERK phosphorylates and activates nuclear targets
such as Elk-1 to upregulate immediate-early genes
such as c-fos. The expression of the immediate-early
genes has been implicated to regulate subsequent in-
duction of delayed early genes, which include cyclin D
[10–12]. Cyclin D-CDK4/6 complex then initiates Rb
phosphorylation, which activates the E2F family of tran-
scription factors and induces the expression of target
genes, including cyclin E. Cyclin E/CDK2 complex fur-
ther phosphorylates Rb and activates the E2F family.
These sequential events, including sequential induction
of a number of genes, lead to the synthesis of proteins
required for S phase entry [13]. Previous studies have
shown that ERK activation is required for not only the in-
duction of immediate-early genes but also the induction
and maintenance of the increased expression of cyclin
D1. As the expression of cyclin D1 occurs several hours
after growth factor stimulation, sustained ERK activa-
tion for at least several hours, not transient activation,
is required for sequential induction of gene expression
and therefore for successful S phase entry [14–17].
Thus, the duration of ERK activity has been implicated
as a critical factor for ensuring G1 phase progression.
In fact, a number of studies have shown the correlation
between sustained ERK activation and successful S
phase entry in various cell lines [18–20]. Then, how sus-
tained ERK activation regulates sequential induction of
gene expression has been a problem to be solved. Re-
cent studies have identified one of the molecular mech-
anisms that answer this question [21, 22]. Thus, only
sustained ERK activation induces sustained phosphory-
lation of immediate-early gene products, which leads to
their stabilization and activation, which are important for
cell-cycle progression from G0/G1 to S phase. However,
it has not been fully elucidated how sustained ERK acti-
vation regulates successful S phase entry.
In this study, our systematic analysis of the effect of the
ERK activity duration on gene expression profiles has
identified a set of genes whose expression levels are
downregulated by ERK activation and return to the origi-
nal levels rapidly after ERK inactivation. This has for the
first time directed our attention to ERK-dependent down-
regulated genes and their function in cell-cycle progres-
sion. Their downregulation is shown to be dependent, at
least in part, on AP-1 activity, suggesting that continuous
downregulation of these genes throughout G1 phase may
act as one of downstream effectors of the immediate-
early gene products stabilized by sustained ERK signal.
Interestingly, many of these ERK-dependent downregu-
lated genes are identified as antiproliferative genes that
have the ability to suppress S phase entry even at mid
or late G1 phase. Our result also demonstrates that ERK
inactivation by the MEK inhibitor or dominant-negative
MEK1 any time before the onset of S phase leads to the
cessation of S phase entry. Collectively, our results
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out G1 phase for successful S phase entry and identify
one of the underlying mechanisms: ERK activity-depen-
dent downregulation of antiproliferative genes. This
mechanism may also be used as a fail-safe mechanism
that prevents inappropriate extracellular stimuli that in-
duce transient ERK activation from promoting cell prolif-
eration, and thus could be a G1 phase progression-mon-
itoring system.
Results
Requirement of Continuous ERK Activation
throughout G1 Phase for S Phase Entry
In quiescent NIH3T3 cells stimulated with FGF or PDGF,
the ERK activation declined to about 10% of the maxi-
mal activation within 3 hr but persisted thereafter, and
the cells entered S phase (Figure 1A, FGF and PDGF).
In contrast, in cells stimulated with EGF or IGF1, the
ERK activation dropped to nearly zero within 3 hr, and
the cells did not enter S phase (Figure 1A, EGF; and
see Figure S4A in the Supplemental Data available
with this article online, IGF1). Thus, our data have indi-
cated a correlation between sustained ERK activation
and successful S phase entry (Figure 1A), in agreement
with previous reports [16, 18, 19]. However, how long
ERK activity should be sustained has not been precisely
determined before. Then, to address this, we added the
MEK inhibitor U0126 to FGF-stimulated cells at varying
times after FGF stimulation and assayed the S phase en-
try at 24 hr (Figure 1B, right). In the absence of U0126,
about half of the NIH3T3 cells began to enter S phase
at around 15 hr after FGF stimulation, and 85% of the
cells entered S phase at 24 hr (see Figure 1B, left).
When U0126 was added before FGF stimulation, no
ERK activation occurred, and the cells failed to enter S
phase (Figure 1A, FGF + U0126). The addition of U0126
at each time point induced almost complete ERK inacti-
vation within 10 min (Figure 1A, FGF + U at 1 hr; and data
not shown). When U0126 was added at 5 hr, only 10% of
the cells were able to enter S phase at 24 hr (Figure 1B,
right, middle). Rather surprisingly, even when U0126
was added at 14 hr, the S phase entry was inhibited by
34.8%, and only 53.4% of cells entered S phase at 24
hr (Figure 1B, right, middle, and bottom). In other words,
the ERK activation for 14 hr (= t053.4) was required for
53.4% of cells to enter S phase. On the other hand,
53.4% of cells entered S phase at 15.7 hr (= t53.4) after
FGF stimulation in the absence of U0126 (Figure 1B,
left). This may imply that sustained ERK activation until
1.7 hr (= t53.4 [15.7 hr] 2 t’53.4 [14 hr]) before the onset
of S phase is required for S phase entry. In fact, the time
differences between the broken line in Figure 1B (left)
and the solid line in Figure 1B (right) (e.g., t43.1 [14.3
hr] 2 t043.1 [11 hr] = 3.3 hr, t25.1 [11 hr] 2 t025.1 [8 hr] =
3 hr) fell within 2–3 hr at any time points after FGF stim-
ulation. This suggests, therefore, that sustained ERK ac-
tivation until about 2 or 3 hr before the onset of S phase is
required for quiescent cells to enter S phase. It should be
noted that ERK5 was not activated significantly in quies-
cent NIH3T3 cells after stimulation by FGF or PDGF (data
not shown). Therefore, activation of ERK1/2 MAPK is
important for cell-cycle progression of NIH3T3 cells,although U0126 is known to inhibit the MEK5/ERK5
pathway as well [23]. To confirm this, we microinjected
a plasmid of S218A/S222A (SASA) MEK1, which is a
dominant-negative form of MEK1 that inhibits ERK1/2
activation but not ERK5 activation, into NIH3T3 cells at
varying time. Cell staining with anti-phospho ERK1/2
antibody showed that ERK1/2 was completely inacti-
vated in the SASA MEK1-injected cells (data not shown).
Considering that it takes about 2–3 hr for the injected
SASA MEK1 plasmid to be expressed, injection of
SASA MEK1 at varying times resulted in the same extent
of inhibition of S phase entry as U0126 addition (Fig-
ure 1B, right, bottom). These results thus demonstrate
that ERK1/2 activation should be sustained until late
G1 for ensuring successful S phase entry.
Sustained ERK Activation Downregulates a Set
of Genes throughout G1 Phase
To identify those genes whose expression levels are
regulated by the ERK pathway during G0/G1 to S phase,
we performed the genome-wide analysis by using Affy-
metrix GeneChip oligonucleotide microarrays, which
contain over 39,000 transcripts and variants, including
about 34,000 well-substantiated mouse genes. Our
analysis showed that sequential induction of immedi-
ate-early genes, cyclin D1, and cyclin E and other E2F
target genes requires ERK activation. This is consistent
with previous reports [24, 25]. On the other hand, our mi-
croarray analysis revealed the existence of ERK-depen-
dent downregulated genes. Here, we have chosen to fo-
cus on those mRNAs whose levels decreased in
response to FGF. First, we identified those genes whose
expression level in FGF-stimulated cells at 4, 7, or 12 hr
was statistically different from the expression level in
unstimulated cells and that in the U0126-treated, FGF-
stimulated cells. In 173 genes out of these genes, the ex-
pression level was decreased by 2-fold or more at either
time point after FGF stimulation, as compared to the ex-
pression level before stimulation, and the degree of the
decrease was reduced by more than 50% by U0126 pre-
treatment in replicate experiments. We defined these
173 genes as ERK-dependent downregulated genes
(Figure 2A and Table S2). The expression level of almost
all of these genes was maintained at a lower level
throughout G1 phase.
We then examined the effect of the ERK activity dura-
tion on expression profiles of these ERK-dependent
downregulated genes. We first compared the gene ex-
pression profiles at 7 hr after FGF stimulation when
U0126 was added before stimulation or added at 1 hr af-
ter stimulation or not added. Rather surprisingly, the ex-
pression profile at 7 hr in the total absence of ERK acti-
vation was very similar to the profile in the presence of
the first 1 hr ERK activation (Figure 2A). This suggests
that strong ERK activation during the initial 1 hr alone
without continued presence of active ERK could not in-
duce decreased expression of these ERK-dependent
downregulated genes at 7 hr. We then examined expres-
sion profiles of the ERK-dependent downregulated
genes at 12 hr after FGF stimulation when U0126 was
added at 7 hr or added before stimulation or not added.
The result showed that the effect of the U0126 addition
at 7 hr on the expression profile at 12 hr is very similar
to that of the addition before stimulation (Figure 2A),
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1173Figure 1. Sustained ERK Activation throughout G1 Phase Is Required for S Phase Entry
(A) Serum-starved NIH3T3 cells were stimulated with bFGF (50 ng/ml), PDGF (20 ng/ml), or EGF (30 ng/ml). U0126 (20 mM) was added 30 min
before (FGF + U0126) or 1 hr after (FGF + U at 1 hr) stimulation. Cells were incubated for 24 hr in the presence of BrdU, fixed, and stained
with anti-BrdU (green). Cell nuclei were also visualized with Hoechst (blue). At the same time, the cell extracts were subjected to immunoblot
analysis with antibodies against ERK and phosphorylated ERK (p-ERK).
(B) Serum-starved NIH3T3 cells were stimulated with bFGF (50 ng/ml) and cultured in the presence of BrdU. At the indicated times after stimula-
tion, the cells were fixed and stained with anti-BrdU antibody (left, upper), and the percentages of BrdU-positive cells were measured (left, middle).
U0126 (final 20 mM) was added to the FGF-stimulated cells at the indicated times after stimulation, and the cells were fixed and stained with anti-
BrdU antibody at 24 hr after FGF stimulation (right, upper). The percentages of BrdU-positive cells were measured (right, middle), and the percent
inhibitions of BrdU incorporation were determined (right, bottom, U0126). More than 100 cells were counted in each sample. Values represent
means6 SD from three independent experiments. An empty vector or an expression plasmid for MEK1 SASA, together with the GFP expression
plasmid, was injected into nuclei of NIH3T3 cells at the same time points as U0126 addition. Cells were incubated for 24 hr after FGF stimulation in
the presence of BrdU, fixed, and stained with anti-BrdU antibody. The injected cells were detected by GFP expression. The percent inhibitions of
BrdU incorporation in the MEK1 SASA-injected cells compared to the empty vector-injected cells were determined (right, bottom, MEK1 SASA).indicating that sustained ERK activation until, or imme-
diately before, 12 hr is required for maintenance of the
decreased expression levels of the ERK-dependent
downregulated genes throughout G1 phase.Identification of the ERK-Dependent Downregulated
Genes as Antiproliferative Genes
We extracted 29 genes, whose decreased expression
levels were almost totally dependent on ERK activity,
Current Biology
1174Figure 2. ERK Downregulates a Set of Antiproliferative Genes during G1 Phase Progression
(A) Expression profiles (left) and average expression profiles (right) of ERK-dependent downregulated genes (173 genes) at 4 hr, 7 hr, or 12 hr after
FGF stimulation when U0126 was added before (+U at20.5 hr), at 1 hr after (+U at 1 hr), or at 7 hr (+U at 7 hr) after stimulation, or not added (2U),
are shown. Each horizontal line displays the expression data for one gene, where the ratio of the mRNA level to its level in the serum-starved (0 hr)
cells is represented by color according to the color scale at the bottom. The entire data set is shown in Table S2.
(B) An empty vector or an expression plasmid for each indicated gene (100 mg/ml), together with the GFP expression plasmid, was injected into
nuclei of serum-starved NIH3T3 cells. After 4 hr, cells were stimulated with bFGF (50 ng/ml) and incubated for 24 hr in the presence of BrdU. Cells
were fixed and stained with anti-BrdU antibody (magenta). The graph shows the percentages of BrdU-positive cells in the injected cells. At least
30 cells were injected for each sample in a series of experiments. The values (means6 SD) were obtained from three to seven independent series
of experiments. Significant differences from the control group (empty vector) are indicated with a single (p < 0.005, Student’s t test) asterisk.by the following four criteria (Table 1). The expression
levels were downregulated at 4, 7, and 12 hr after FGF
stimulation (by more than 2.5-fold change at least at
one time point). The FGF-dependent decrease in the
expression levels was almost completely suppressed
by prior treatment with U0126. Their downregulation
was not induced by the initial 1 hr ERK activation alone.
Their downregulated expression levels returned to theoriginal or higher levels at 12 hr when U0126 was added
at 7 hr after stimulation. Quantitative RT-PCR analysis of
all of the genes in Table 1 confirmed the array data
(Figure 3A and Figure S1). This list includes JunD [26],
Gadd45a [27], Ddit3 [28], and Tob1 [29, 30], which are
known to regulate cell-cycle progression negatively. In
particular, Tob1 and Ddit3, also known as CHOP or
GADD153, were shown to inhibit cell-cycle progression
ERK Downregulates Antiproliferative Genes
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Genbank
Accession No. Gene Description
Antiproliferative
Abilitya
AJ010605 Sox6 SRY box containing gene 6 +
BB548889 Gpr133 G protein-coupled receptor 133
BC027250 1110018M03Rik
NM_011018 Sqstm1 sequestosome 1
BQ175796 Pak3 p21 (CDKN1A)-activated kinase 3 2
NM_010592 Jund1 Jun proto-oncogene related gene d1 +
BB417145 Gpr23 G protein-coupled receptor 23
BM120193 Nudt18 nudix (nucleoside diphosphate linked moiety X)-type motif 18 (MGC38179) 2
BM117918 Dtna dystrobrevin a
NM_007837 Ddit3 DNA damage-inducible transcript 3 +
NM_007836 Gadd45a growth arrest- and DNA damage-inducible 45 a +
BE945188 1110002M09Rik
AK020810 A930005F02Rik
AK018112 6330404C01Rik
AI267126 Klf9 Kruppel-like factor 9 2
BB408123 RGC32 response gene to complement 32 2
BB383709 C230029M16
BG070342 Cpeb4 cytoplasmic polyadenylation element binding protein 4 +
NM_133943 Hsd3b7 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7
AI426175 Hsc20 J-type cochaperone HSC20
AK017272 Lpl lipoprotein lipase
NM_008606 Mmp11 matrix metalloproteinase 11 2
BC026841 Mef2c myocyte enhancer factor 2C +
AV023018 1190030G24
NM_008608 Mmp14 matrix metalloproteinase 14 2
AA242096 Tob1 transducer of ErbB-2.1 +
NM_010286 Gilz glucocorticoid-induced leucine zipper +
BC003438 Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1
BG067878 Arfgap3 ADP-ribosylation factor GTPase activating protein 3 2
a Fifteen genes in this list were cloned and injected into serum-starved NIH3T3 cells, and the effect on the FGF-induced S phase entry of the cells
was examined. + denotes the genes that inhibited the S phase entry. 2 denotes the genes that failed to inhibit the S phase entry.from G0/G1 to S phase [28–30]. Therefore, we hypothe-
sized that other genes in this list could also have the abil-
ity to inhibit cell-cycle progression from G0/G1 to S
phase. To test this idea, we picked up 15 genes from
this list and examined their ability to inhibit S phase en-
try. Serum-starved NIH3T3 cells were microinjected with
an expression plasmid for each of these 15 genes and
stimulated with FGF. Cells expressing each gene were
detected by the coinjected GFP expression, and
whether or not the cells entered the S phase at 24 hr
was determined by BrdU incorporation. Representative
results are shown in Figure 2B, which demonstrates that
JunD, Gadd45a, Sox6, Ddit3, Gilz, Cpeb4, and Mef2c
have the ability to inhibit the S phase entry, whereas nei-
ther Pak3, Nudt18 (MGC38179), nor Klf9 inhibits S phase
entry. At least three independent experiments for the 15
genes gave essentially the same results (Figure 2B and
Table 1). Thus, in total, eight out of fifteen genes in the
list are found to be antiproliferative genes (Table 1).
We then performed siRNA experiments. We designed
and synthesized three siRNA duplexes that target each
of the all eight genes. Our results showed that each
siRNA successfully reduced the target mRNA levels sig-
nificantly (Figure S2A and data not shown). Then we ex-
amined the effect of individual siRNA treatment on S
phase entry in the presence of EGF, which is not a potent
mitogen in NIH3T3 cells. The obtained results showed
that all the three siRNA duplexes for each of Cpeb4,
Gadd45a, and Tob1 enhanced S phase entry
(Figure S2B). These results suggest that downregulation
of these antiproliferative genes facilitates G1 phaseprogression to S phase. Next, to determine where in
G1 phase these antiproliferative genes have an inhibiting
effect, we examined the state of Rb phosphorylation at
Ser807/Ser811 in FGF-stimulated NIH3T3 cells to which
each of these eight antiproliferative genes was microin-
jected. The repeated experiments demonstrated that
JunD, Gadd45a, and Cpeb4 markedly inhibited the Rb
phosphorylation, and Mef2c and Tob1 inhibited it mod-
erately (Figure S3). All these results have shown that
some of the ERK-dependent downregulated genes are
antiproliferative genes and thus led to the idea that suc-
cessful S phase entry may require the decreased ex-
pression levels of these antiproliferative genes until the
onset of S phase.
Continuous ERK Activation throughout G1
Phase Induces and Maintains the Decreased
Expression Levels of Antiproliferative
Genes to Allow S Phase Entry
To test this idea, we first measured the time course of
the change in the expression levels of these antiprolifer-
ative genes by quantitative RT-PCR in more detail. FGF
and PDGF induced the marked decrease in mRNA levels
of these eight antiproliferative genes, and their de-
creased expression levels were maintained throughout
G1 phase (Figure 3A and data not shown). In contrast,
TPA, which induced shorter ERK activation than FGF
(Figure S4A), also induced the decrease in their expres-
sion levels, but the decrease was transient, and the ex-
pression levels were not maintained (Figure S4B). More-
over, EGF or IGF1, which induced only very short ERK
Current Biology
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(A) Serum-starved NIH3T3 cells were stimulated with bFGF (50 ng/ml) and treated with U0126 (20 mM) at 30 min before or 6 hr or 10 hr after stim-
ulation. At indicated times after initial FGF stimulation, relative mRNA levels of the indicated genes were determined by quantitative RT-PCR.
(B) Serum-starved NIH3T3 cells were stimulated with 10% FCS. At 4 hr after stimulation, the cells were acid washed and then cultured in serum-
free medium. Cells were incubated for 24 hr after initial stimulation in the presence of BrdU, fixed, and stained with anti-BrdU antibody (green).
Cell nuclei were also visualized with Hoechst (blue). At the same time, the cell extracts were subjected to immunoblot analysis with antibodies
against ERK and phosphorylated ERK (p-ERK), and relative mRNA levels of the indicated genes were determined.
(C) Serum-starved NIH3T3 cells were stimulated with PDGF at each concentration (1, 2, 5, 20, ng/ml). At indicated times after stimulation, the cell
extracts were subjected to immunoblot analysis with antibodies against ERK and phosphorylated ERK (p-ERK) (left), and relative mRNA levels of
JunD were determined (middle). The percentages of the BrdU-positive cells for 24 hr after stimulation were shown (right).activation, did not decrease their expression levels
(Figure S4). The decreases by FGF were completely in-
hibited by the U0126 pretreatment. Moreover, theaddition of U0126 at 6 hr or 10 hr after FGF stimulation
resulted in a rapid increase in their expression levels,
reaching the levels that were attained by the U0126
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1177treatment before stimulation (Figure 3A). Essentially the
same results were obtained when we used PD098059,
another MEK inhibitor, instead of U0126. Therefore, con-
tinuous ERK activation is required for induction and
maintenance of the decreased expression levels of
these genes. Moreover, it should be pointed out that mi-
togenic signal-dependent downregulation of these anti-
proliferative genes was commonly observed in other cell
types, including normal rat kidney (NRK) cells and hu-
man embryonic WI-38 cells. For example, stimulation
with 10% FCS induced ERK-dependent downregulation
of all eight genes and six genes (except for Cpeb4 and
Mef2c) in NRK cells and WI38 cells, respectively (data
not shown).
It is well known that continuous exposure to growth
factor is required for quiescent cells to enter S phase.
In our experiments, readdition of 10% FCS to quiescent
NIH3T3 cells induced sustained ERK activation and S
phase entry (Figure 3B, upper, left). FCS withdrawal at
4 hr resulted in rapid ERK inactivation and cessation of
S phase entry (Figure 3B, upper, right). While FCS, like
FGF and PDGF, induced and maintained the decreased
expression levels of the eight antiproliferative genes, the
FCS withdrawal at 4 hr led to a rapid increase in the ex-
pression levels of all these downregulated genes
(Figure 3B, lower). Therefore, sustained ERK activation
was required for the maintenance of the decreased ex-
pression levels of the antiproliferative genes. It has
been reported that the ERK activity duration and the S
phase entry depend on the PDGF concentration [22].
Then, we examined the JunD mRNA level as well as
ERK activity and S phase entry in the presence of vary-
ing concentrations of PDGF. The result showed that
both the ERK activity duration and the duration of the
decreased expression level of JunD mRNA become lon-
ger with increased PDGF concentration, in parallel with
the increase in the S phase entry (Figure 3C). Thus, there
was a good correlation between the ERK activity dura-
tion and the continuous downregulation of antiprolifera-
tive genes.
To evaluate the physiological role of the ERK-depen-
dent downregulation of antiproliferative genes in cell-
cycle progression, it is important to know whether en-
dogenous expression levels of these genes block S
phase entry. Anti-JunD antibody is available to estimate
the JunD protein level in individual cells. Both immuno-
blotting and cell staining with the anti-JunD antibody
showed that the changes of endogenous JunD protein
level in response to FGF and U0126 roughly paralleled
those of the mRNA level (Figure 4A and data not shown).
Thus, JunD protein is downregulated by ERK activity
and increases to the original level or a slightly higher
level soon after ERK inactivation. As the expressed pro-
tein level depends on the plasmid concentration that is
injected into the nucleus, the experiment with increasing
the concentrations of the JunD expression plasmid en-
ables us to estimate the relationship between the in-
jected plasmid concentration and the expressed protein
level. Our data indicated that endogenous JunD protein
level in the presence of U0126 15 hr after FGF stimula-
tion roughly corresponds to the expressed JunD protein
level resulting from the injection of 10 mg/ml JunD plas-
mid (Figure 4B). Figure 4C shows that JunD inhibited
FGF-stimulated S phase entry in a dose-dependentmanner, and at the JunD expression plasmid concentra-
tion of 10 mg/ml the S phase entry was inhibited by about
40%. Thus, nearly endogenous levels of JunD signifi-
cantly suppress S phase entry. Moreover, we have
found that JunD and Gadd45a have an additive inhibi-
tory effect on S phase entry. JunD is thought to antago-
nize other Jun family proteins such as c-Jun to inhibit the
AP-1 activity in NIH3T3 cells [26]. Our microinjection ex-
periment has shown that coexpression of c-Fos mark-
edly suppresses the S phase entry-inhibiting ability of
JunD, but not that of Gadd45a (data not shown). This
suggests that these two antiproliferative genes differ in
their respective target to inhibit S phase entry. In fact,
coexpression of JunD and Gadd45a showed an additive
effect (Figure 4C), although the antiproliferative effect
of JunD or Gadd45a alone was modest at low doses
(Figure 4C).
Importantly, we have further found that forced expres-
sion of these antiproliferative genes at low doses even in
late G1 phase inhibits S phase entry. When JunD and
Gadd45a plasmids at low doses were coinjected at 2
hr or 8 hr after FGF stimulation, S phase entry was
strongly inhibited: the extent of the inhibition by injection
at 2 hr or 8 hr was almost the same as that by injection
before FGF stimulation (Figure 4D). This result suggests
that if the downregulation of the antiproliferative genes
is broken during G1 phase and their expression levels
return to their original levels, the cells should cease to
enter S phase. Thus, all these results, taken together,
strongly suggest that successful S phase entry requires
the decreased expression levels of these antiprolifera-
tive genes throughout G1 phase, which are induced
and maintained by sustained ERK activation.
ERK Activation Alone Is Capable of Inducing
Downregulation of Several Antiproliferative Genes
We then examined whether the activation of the ERK
pathway alone is able to decrease the expression levels
of these antiproliferative genes. We used NIH3T3 cells
expressing DB-Raf:ER (estrogen receptor) [31]. B-Raf
is known to function as a specific and direct activator
of MEK, and in DB-Raf:ER cells the addition of estrogen
or 4-hydroxy tamoxifen (4-HT) induces immediate and
continuous ERK activation (data not shown). The addi-
tion of 4-HT resulted in a significant decrease in the ex-
pression levels of five out of eight antiproliferative genes
(Figure 5A). It should be noted that 4-HT induces neither
ERK activation nor downregulation of these genes in
normal NIH3T3 cells (data not shown). Thus, sustained
ERK activation is sufficient for induction and mainte-
nance of the decreased expression levels of part of the
ERK-dependent downregulated genes.
Downregulation of the Antiproliferative Genes
Mostly Requires AP-1 Activity
In our preliminary experiment, treatment with cyclohexi-
mide inhibited completely the FGF-dependent downre-
gulation of JunD and Gadd45a mRNA (data not shown),
indicating requirement of de novo protein synthesis for
the downregulation. In addition, our analyses with the
chromatin immunoprecipitation (ChIP) assay with anti-
RNA polymerase II antibody and the reporter assay
have suggested that ERK activation leads to downregu-
lation of JunD and Gadd45a by inducing transcriptional
Current Biology
1178Figure 4. ERK Promotes the G1 Phase Cell-Cycle Progression by Downregulating Antiproliferative Genes
(A) Serum-starved NIH3T3 cells were stimulated as in Figure 3A. At indicated times, the cell extracts were subjected to immunoblot analysis with
anti-JunD and anti-ERK antibodies, and the cells were stained with anti-JunD antibody.
(B) An expression plasmid for Myc-tagged JunD (0.1, 1, 10, 100, or 500 mg/ml), together with the GFP expression plasmid, was injected as in
Figure 2B. After 4 hr, cells were stimulated with bFGF (50 ng/ml) and incubated for 15 hr. Cells were fixed and stained with anti-JunD antibody.
(C) An empty vector, Myc-tagged JunD or Myc-tagged Gadd45a (10, 20, 100, or 500 mg/ml) or both Myc-tagged JunD and Myc-tagged Gadd45a
(10 mg/ml for each) were injected as in Figure 2B. The percentages of BrdU-positive cells were measured. The values (means6SD) were obtained
from three to seven independent series of experiments. Significant differences from the control group (empty vector) or between indicated
samples are indicated with a single (p < 0.05, Student’s t test) or double (p < 0.01, Student’s t test) asterisk.
(D) Both Myc-tagged JunD and Myc-tagged Gadd45a at low doses (10 mg/ml for each) were injected into nuclei of NIH3T3 cells at various time
points after FGF stimulation. Cells were incubated for 24 hr after FGF stimulation in the presence of BrdU, fixed, and stained with anti-BrdU
antibody. The graph shows the percentages of BrdU-positive cells in the injected cells.repression, rather than enhancing mRNA degradation
(data not shown). We supposed then that the downregu-
lation might depend on AP-1 activity, as AP-1 transcrip-
tion factors are shown to be differentially regulated by
the different ERK activity duration [21, 22, 32]. To inves-
tigate requirement of AP-1 activity for the downregula-
tion of these antiproliferative genes, we used a lentivirus
harboring A-Fos, a dominant-negative form of c-Fos.
A-Fos contains a substitution of the basic DNA binding
domain with an acidic sequence that enhances the
stability of interaction with Jun partners but abolishes
DNA binding [33]. Thus, A-Fos can inhibit the activity of
Fos family members. Indeed, our reporter assay demon-
strated that A-Fos expression by the lentivirus infectioninhibited AP-1 activity by more than 90%, and coexpres-
sion of c-Fos was able to overcome the inhibitory effect
of A-Fos (Figure 5B, left). The effect of A-Fos expression
on the FGF-dependent downregulation of the eight anti-
proliferative genes was examined by quantitative RT-
PCR. A-Fos expression almost completely inhibited the
downregulation of Sox6, JunD, Ddit3, Gadd45a, and
Cpeb4; partially inhibited that of Mef2c and Tob1; and
failed to inhibit that of Gilz (Figure 5B, right), indicating
that the ERK-dependent downregulation of these anti-
proliferative genes mostly requires AP-1 activity. Among
these AP-1-regulated genes (Sox6, JunD, Ddit3,
Gadd45a, and Cpeb4), JunD and Ddit3 promoters were
found to contain putative consensus sequences that
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(A) Serum-starved DB-Raf:ER NIH3T3 cells were treated with 4-HT. At indicated times after 4-HT treatment, relative mRNA levels of the indicated
genes were determined.
(B) NIH3T3 cells were infected with an A-Fos expression vector or a control vector by lentivirus followed by cotransfection with a reporter plasmid
(pAP-1-Luc) and a c-Fos expression plasmid. The luciferase activity was measured 24 h after transfection. The data represent means and
standard deviations in triplicate (left). Serum-starved NIH3T3 cells, which had been infected with an A-Fos expression vector or a control vector
by lentivirus, were treated with FGF. At indicated times after FGF treatment, relative mRNA levels of the indicated genes were determined (right).
(C) Summary of (A) and (B). Raf-ER; + denotes the gene that was significantly downregulated by 4-HT in DB-Raf:ER NIH3T3 cells. AP-1; ++ and +
denote the genes whose downregulation was inhibited completely or partially by A-Fos, respectively.could bind to AP-1 family members (data not shown), as
was reported previously [34, 35]. To determine whether
or not AP-1 directly affects any of the target genes, we
carried out the ChIP assay using anti-c-Fos and anti-
c-Jun antibodies. The obtained results demonstrated
that c-Fos and c-Jun could bind to the promoter regions
in endogenous JunD and Ddit3 genes (Figure S5). There-
fore, these two genes could be regulated by AP-1directly. Figure 5C summarizes the results of theDB-Raf:
ER and the A-Fos expression experiments. No correla-
tion was found between the ERK pathway sufficiency
and the AP-1 activity requirement among the eight genes
in terms of their downregulation mechanisms. Thus,
there may be several different mechanisms that mediate
the ERK-dependent downregulation of antiproliferative
genes.
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uous ERK Activation in G1 Phase Progression
Sustained ERK activation throughout G1
phase in response to mitogenic signals in-
duces and maintains decreased expression
levels of antiproliferative genes and thus
allows S phase entry (left). Transient ERK acti-
vation does not induce or maintain decreased
expression levels of antiproliferative genes
and thus is unable to cause S phase entry
(right).Discussion
The duration of ERK activity has been implicated in di-
verse biological processes as a crucial factor for deter-
mining cell fate decisions [3]. In PC12 cells, sustained
ERK activation induced by NGF leads to differentiation
into sympathetic-like neurons, whereas transient activa-
tion induced by EGF results in proliferation of the cells
[36–38]. On the other hand, sustained ERK activation
has been shown to be required for growth factor-stimu-
lated G1 phase progression to S phase in fibroblastic
cells [18–20]. However, how long ERK activity should
be sustained has not been precisely determined. More-
over, it has remained unclear how sustained ERK activa-
tion regulates gene expression programs in mid or later
stages of G1 phase to promote cell-cycle progression.
In this study, we have first demonstrated that the long
and continuous ERK activation throughout G1 phase in
response to mitogenic signals is required for S phase
entry. Our results have shown that when ERK is inacti-
vated even in late G1 phase, the cells cease to enter S
phase. Our results have further demonstrated that there
are ERK-dependent downregulated genes, some of
which are found to have the ability to suppress S phase
entry. Their downregulation is induced and maintained
by continuous ERK activation throughout G1 phase,
and their decreased expression levels return to the orig-
inal levels rapidly after ERK inactivation (Figure 6). Fur-
thermore, their forced expression to endogenous levels
before growth factor stimulation even in late G1 phase
blocks S phase entry. Therefore, our results reveal not
only the requirement of continuous ERK activation
throughout G1 phase for successful S phase entry but
also a novel role of continuous ERK activation in G1
phase progression, continuous downregulation of anti-
proliferative genes throughout G1 phase to allow cell-
cycle progression (Figure 6). This mechanism has been
hitherto unidentified, partly because previous studies
have focused on ERK-dependent upregulated genes
such as immediate-early genes and cyclins, which play
an essential role in driving cell-cycle progression.
Thus, growth factor-stimulated continuous ERK activa-
tion may function to ensure G1 phase progression by
not only upregulating proliferation-promoting genes
but also downregulating antiproliferative genes.
An intriguing idea is that cells also utilize this novel
mechanism, that is, the ERK-dependent downregulationof antiproliferative genes as a system to monitor extra-
cellular stimuli. The cells receive not only mitogenic sig-
nals but also diverse stimuli such as environmental
stresses that induce transient ERK activation. As tran-
sient ERK activation does not induce sustained downre-
gulation of antiproliferative genes, these inappropriate
stimuli do not cause cell proliferation. Thus, this mecha-
nism may work as a fail-safe mechanism, which pre-
vents inappropriate stimuli from causing cell-cycle pro-
gression. In this study, we presented several such
examples. Cessation of growth factor stimulation (FCS
withdrawal) at mid G1 phase or insufficiency of mitogen
doses (PDGF concentrations) resulted in transient ERK
activation that could not maintain the decreased expres-
sion levels of antiproliferative genes and thereby led to
the cessation of S phase entry. In addition, recent stud-
ies have shown that loss of adhesion to an extracellular
matrix (ECM) causes the transient ERK activation and
the failure of S phase entry even after strong mitogenic
stimuli [12]. Therefore, cells progressing through G1
phase may monitor environmental conditions through
the ERK activation status, by which gene expression
programs are controlled to generate an appropriate
response.
Recently, it has been shown that several transcription
factors including the Fos family proteins and other im-
mediate-early gene products, which have a docking
site for ERK, termed the FXFP (DEF) domain, detect
the ERK activity duration. The increase in the ERK activ-
ity duration is reflected by the increased and sustained
phosphorylation of these transcription factors, which in-
creases their stability and activity to elicit the biological
outcome, such as induction of cyclin D1 expression [21,
22]. Our results have shown that AP-1 activity is re-
quired for the downregulation of most of the ERK-de-
pendent downregulated, antiproliferative genes identi-
fied here. Therefore, continuous downregulation of
these genes throughout G1 phase may act as one of
the downstream effectors of the Fos family proteins
that are stabilized by sustained ERK activity. It should
be pointed out, however, that the extent of the depen-
dence on AP-1 activity varies among these downregu-
lated genes, and the efficiency of ERK activity for down-
regulation also differs among these genes. Thus, how
growth factor stimulation downregulates these antipro-
liferative genes may not be accounted for by a single
mechanism. Future work should address the detailed
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spective genes.
It is well known that CDK inhibitors function as negative
regulators of cell-cycle progression [13]. In particular,
p27KIP1 and p21WAF1/CIP1, members of the Cip/Kip family,
have been shown to be associated with G1/S transition in
response to growth factor stimulation. It has been shown
that high intensity of sustained ERK activation, which is
achieved by high level expression of active Raf-1, in-
duces cell-cycle arrest through p21WAF1/CIP1 upregula-
tion [39, 40]. In contrast, moderate or low ERK activation,
which is seen in normal mid or late G1 phase, is not suffi-
cient to maintain the induction of p21WAF1/CIP1 expres-
sion. Therefore, p21WAF1/CIP1 expression is thought to
be a sensor of the magnitude, not the duration, of ERK ac-
tivation. On the other hand, growth factor stimulation
leads to p27KIP1 downregulation through transcriptional
and posttranscriptional mechanisms, which are medi-
ated by the PI3K-AKT and ERK pathways. Our microarray
and quantitative RT-PCR analyses have shown that FGF
stimulation reduces the expression level of p27KIP1 in an
ERK-independent manner (data not shown), although
previous reports have suggested that the ERK pathway
regulates p27KIP1 expression at the posttranslational
level [41]. Our present study has identified a number of
antiproliferative genes whose mRNA expression levels
are downregulated in an ERK-dependent manner. These
genes do not include CDK inhibitors and had not been
clearly demonstrated to have the ability to inhibit S phase
entry, except for Tob1 and Ddit3. The next challenge,
therefore, will be elucidation of the molecular mecha-
nisms by which these antiproliferative genes block S
phase entry. The action mechanism of Tob1 has been rel-
atively well studied, and Tob1 has beenshown to regulate
cyclin D1 expression negatively by recruiting histone de-
acetylase (HDAC) to the cyclin D1 promoter [42]. JunD
was also shown to inhibit cyclin D1 expression, and it
may exert this effect, probably through antagonizing
the function of c-Jun [43]. Gadd45a and Ddit3, also
known as Gadd153 or CHOP, which are both induced
by DNA damaging agents and growth arrest signals,
have been suggested to be involved in regulation of G1/
S transition as well, but little is known about their target
molecules in leading to G1/S arrest [28, 44]. Our result
that c-Fos expression cancels the inhibitory effect of
JunD, but not that of Gadd45a, has suggested that
JunD and Gadd45a differ in their respective target to sup-
press G1 phase progression. Gilz was shown to suppress
ERK activation by inhibiting phosphorylation of Raf-1
[45], implying that the ERK pathway may form a positive
feedback loop by downregulating the inhibitor of its
own pathway. Two transcription factors, MEF2C and
Sox6, which are known to regulate cell differentiation
[46, 47], are here also shown to have the ability to sup-
press G1 phase progression. Although cell differentiation
is often associated with the cell-cycle arrest, cell differen-
tiation-regulating genes do not necessarily have the abil-
ity to inhibit cell-cycle progression. So both Mef2C and
Sox6 might inhibit G1 phase progression directly through
acting on their specific target molecules, which are not
known at present. Little is known about the function of
Cpeb4 [48], a member of cytoplasmic polyadenylation el-
ement binding (CPEB) proteins. Thus, all the identified
antiproliferative genes may differ in their target moleculesto suppress G1 phase progression. Identification of these
target molecules or genes will provide new insights into
G1 phase progression.
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